Novo-owned Xellia prepares for launch of own products: "It's been a long journey"
Denmark's Xellia Pharmaceuticals will soon transition from being a supplier of anti-infective drugs to a pharma company with its own products on the market. According to the CEO, it has been an "interesting journey" that began when Novo Holdings acquired the company in 2013.
Copenhagen-based Xellia Pharmaceuticals is about to complete a transformation that began when Novo Holdings acquired the company in 2013 for USD 700 million.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Xellia invests millions in Danish facilities
For abonnenter
Xellia acquires US production plant
For abonnenter
Xelia buys US facilitites
For abonnenter
